Drug Profile
Research programme: attention deficit hyperactivity disorder therapeutics - ITL Pharma
Alternative Names: Pim2; PolyPhetamineLatest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator ITL Pharma
- Class Amines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder in USA (Tablet)
- 21 Feb 2017 Research programme: attention deficit hyperactivity disorder - ITL Pharma is available for licensing as of 21 Feb 2017. http://www.itlpharmaceuticals.com/investors.html
- 21 Feb 2017 Early research in Attention-deficit hyperactivity disorder in USA (unspecified route)